Posted by Michael Wonder on 30 Jul 2025
Health Canada expands approval of Scemblix, making it an option for newly diagnosed and previously treated chronic myeloid leukaemia patients
30 July 2025 - Scemblix is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial versus all standard of care therapies.
Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Scemblix (asciminib tablets) for adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who are newly diagnosed or who have previously received one or more tyrosine kinase inhibitors.
